Campbell Alliance to Release New Forward-Looking Industry Report on Deal-Making Trends at the 2013 BIO International Convention

     Campbell Alliance to Release New Forward-Looking Industry Report on
         Deal-Making Trends at the 2013 BIO International Convention

PR Newswire

NEW YORK, April 19, 2013

NEW YORK, April 19, 2013 /PRNewswire/ --Campbell Alliance, an inVentiv Health
company and an industry leader in biopharmaceutical and medical technology
consulting, will release the results of its fifth annual Dealmakers'
Intentions study during a Super Session at the 2013 BIO International
Convention in Chicago, Ill., at McCormick Place.

The Dealmakers' Intentions 2013 study results represent input from all the
major pharmaceutical markets, capturing expectations for deal activity, supply
and demand for assets at different stages of development, and approaches to
valuation. Interesting findings to emerge from the study include:

  oAcquisitions with earn outs have filled the void created by the decline of
    traditional licensing.
  oBoth in-licensers and out-licensers have a positive outlook for 2013.
  oIn-licensers are more interested in early-stage assets than seen in
    previous study years.
  oMore than half of the time when deals fail, they fail for reasons that are
    within the control of the negotiating teams.
  o2013 may be a sellers' market for later-stage oncology, antibiotic, and
    vaccine assets.
  oThere continues to be a relative over-supply of early-stage oncology
    assets.
  oOrphan products and antibody-drug conjugates are expected to be the top
    two "hot" areas for licensing in 2013.

"Dealmakers on both sides of the table should be prepared for 2013 to be one
of the most active years in recent history," said Jeff Stewart, Director,
Corporate Development Center of Excellence, Campbell Alliance. "This will be
driven by the increasing need for out-licensers to access capital and
in-licensers to access new products. The discount rate spread has increased
to the point where valuations that were simply too far apart in 2012 now can
be fully in line even in the face of different commercial projections."

Specifically for in-licensers, 2013 may be a great time to pursue early-stage
oncology assets, while they can expect to face competition for clinical-stage
and marketed oncology assets. Similarly, early-stage antibiotic and
dermatology assets are relative buyers' markets. Other therapeutic areas are
relative sellers' markets and must be approached with due consideration. It
is important for in-licensers to remain objective in valuing assets and to
carefully weigh the organizational fit of assets under consideration.

"For out-licensers, the market appears to be shifting in their favor," added
Stewart. "To turn this positive outlook into successful deals, however,
out-licensers will need to provide more pricing and market access
justification in their non-confidential materials and bridge the valuation gap
through credible validation of the commercial opportunity."

A summary of the study results will be presented during a Super Session at the
BIO International Convention on Wednesday, April 24 at 2:00pm CT, followed by
a panel discussion involving senior industry executives. Panelists for this
Super Session will include:

  oWilliam Hait, MD, PhD – Global Head, Janssen Research & Development LLC,
    Janssen
  oBahija Jallal, PhD – Executive Vice President, R&D, MedImmune
  oJohn Leonard, MD – Senior Vice President, Chief Scientific Officer, AbbVie
  oRoger Pomerantz– Worldwide Head of Licensing & Acquisitions, Senior Vice
    President, Merck Research Labs
  oChihiro Yokota, RPh – Corporate Executive, Global Head, Business
    Development and Licensing& Alliances, Astellas Pharma Inc.

Additional information about Dealmakers' Intentions 2013, including access to
a white paper summary of the results, is available here:
http://www.campbellalliance.com/dealmakers.

About Campbell Alliance
Campbell Alliance, an industry leader in biopharmaceutical and medical
technology consulting, is the Consulting business segment of inVentiv Health,
a leading global provider of best-in-class clinical, commercial, and
consulting services to companies seeking to accelerate performance. The
firm's clients include all of the world's top-20 pharmaceutical companies, as
well as numerous emerging and midsize firms. Campbell Alliance is organized
into three Centers of Excellence—Commercial, Medical, and Corporate
Development—each of which offers a range of services to a critical area of the
pharmaceutical, biotechnology, and medical technology industries. Each of our
Centers of Excellence is a dedicated consulting team whose members are highly
specialized and offer deep expertise in their chosen areas. From its
locations in New York City, Raleigh, NC, Parsippany, NJ, Los Angeles, San
Francisco, Chicago, Boston, Philadelphia, Atlanta, London and Zurich,
Switzerland, the firm serves clients throughout North America, Europe, and
Japan. For more information on Campbell Alliance, please visit
http://www.campbellalliance.com.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical,
commercial and consulting services to companies seeking to accelerate
performance. inVentiv offers convergent services that deliver extraordinary
outcomes to clients whose goal is improving human life. In 40 countries around
the world, inVentiv's 13,000 employees help clients rapidly transform
promising ideas into commercial reality. inVentiv clients include more than
550 pharmaceutical, biotech and life sciences companies, as well as companies
that now see health as part of their mission. inVentiv Health, Inc. is
privately owned by inVentiv Group Holdings, Inc., an organization sponsored by
affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members
of the inVentiv management team. For more information, visit
http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause our performance to
differ materially. These forward-looking statements reflect our current views
about future events and are subject to risks, uncertainties and assumptions.
We wish to caution readers that certain important factors may have affected
and could in the future affect our actual results and could cause actual
results to differ significantly from those expressed in any forward-looking
statement. Such factors include, without limitation: the impact of our
substantial level of indebtedness on our ability to generate sufficient cash
to fulfill our obligations under our existing debt instruments or our ability
to incur additional indebtedness; the impact of customer project delays and
cancellations and our ability to sufficiently increase our revenues and manage
expenses and capital expenditures to permit us to fund our operations; the
impact of the consummation of any future acquisitions; the impact of any
change in our ratings and the ratings of our debt securities on our
relationships with customers, vendors and other third parties; the impact of
any additional leverage we may incur on our ratings and the ratings of our
debt securities; our ability to continue to comply with the covenants and
terms of our senior secured credit facilities and to access sufficient capital
under our credit agreement or from other sources of debt or equity financing
to fund our operations; the impact of any default by any of our credit
providers; our ability to accurately forecast costs to be incurred in
providing services under fixed price contracts; our ability to accurately
forecast insurance claims within our self- insured programs; the potential
impact of pricing pressures on pharmaceutical manufacturers from future
healthcare reform initiatives or from changes in the reimbursement policies of
third-party payers; our ability to grow our existing client relationships,
obtain new clients and cross-sell our services; the potential impact of
financial, economic, political and other risks, including interest rate and
exchange rate risks, related to conducting business internationally; our
ability to successfully operate new lines of business; our ability to manage
our infrastructure and resources to support our growth; our ability to
successfully identify new businesses to acquire, conclude acquisition
negotiations and integrate the acquired businesses into our operation, and
achieve the resulting synergies; the resolution of purchase price adjustment
disputes in connection with our recent acquisitions and related impacts; any
disruptions, impairments, or malfunctions affecting software as well as
excessive costs or delays that may adversely impact our continued investment
in and development of software; the potential impact of government regulation
on us and on our client base; our ability to comply with all applicable laws
as well as our ability to successfully adapt to any changes in applicable laws
on a timely and cost effective basis; our ability to recruit, motivate and
retain qualified personnel, including sales representatives; the possibility
that client agreements will be terminated or not renewed; any potential
impairment of goodwill or intangible assets; consolidation in the
pharmaceutical industry; changes in trends in the healthcare and
pharmaceutical industries or in pharmaceutical outsourcing, including
initiatives by our clients to perform services we offer internally; our
ability to convert backlog into revenue; the potential liability associated
with injury to clinical trial participants; the actual impact of the adoption
of certain accounting standards; and our ability to maintain technological
advantages in a variety of functional areas, including sales force automation,
electronic claims surveillance and patient compliance. Holders of our debt
instruments are referred to reports provided to investors from time to time
and the offering memoranda provided in connection with the issuance of our
notes for further discussion of these risks and other factors.

Media Contact

James Forte
Vice President, Marketing
jforte@campbellalliance.com

SOURCE Campbell Alliance

Website: http://www.campbellalliance.com